The Ankylosing Spondylitis Market, in terms of revenue, was valued at US$ 5.34 Bn in 2020 and is expected to reach US$ 6.84+ Bn by 2030.Ankylosing Spondylitis (AS) is a common chronic inflammatory rheumatic disease, which are seen in young adults, often in their late teens or early twenties. It can cause pain in lower back and neck. Over the time, AS can cause spine to become curved and rigid and affecting the shape of spine. Normally AS causes pain in spine but in some cases AS can cause swelling and pain in heels, chest, hips and shoulders. Early diagnosis is crucial in ankylosing spondylitis as spinal deformity can be minimized with the help of proper treatment.

Competitive Outlook: AbbVie Inc, Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi Aventis, CELGENE Corporation, Celltrion Healthcare Co., Ltd., Eisai Co., Ltd., Galapagos NV, Protalix Ltd., Regeneron Pharmaceuticals, Inc., Shanghai Pharmaceuticals Holding Co., Ltd, UCB S.A., and Xian Janssen Pharmaceutical Ltd amongst others.

Get Full Information of this premium report: https://www.absolutemarketsinsights.com/reports/Ankylosing-Spondylitis-Market-2018-2026-123

Global Ankylosing Spondylitis Market, By Application

There is no cure for AS, but have several approved treatments to manage the symptoms, such as anti-inflammatory drugs, over-the-counter pain relievers, prescription medicines, as well as exercise program. Many research institutes are working on various therapy and diagnosis of ankylosing spondylitis. Radiographic studies are also helpful in the detection, diagnosis and monitoring of AS patients. Also, computed tomography can be used in some selected situations such as bone formations at various sites, sclerotic changes and erosions.

Ankylosing Spondylitis Market, by Region

Asia Pacific region represents a lot of opportunities for future growth in the market. The organizations and institutes in this region are investing heavily in R&D as there are not any approved treatments available for this disease. For instance, Novartis Pharmaceuticals in Japan is currently carrying clinical trial on patients for clinical efficacy and safety of secukinumab subcutaneous injections for the treatment of ankylosing spondylitis. The study was started in April 2016 and expected to complete in November 2018.

Competitive Market Share

The ankylosing spondylitis market report provides both, qualitative and quantitative research of the market, as well as it helps to gain important insights of current and future market and trending technologies adopted by the key players. The report also offers extensive research on the key players in this market and detailed insights on the competitiveness of these players. The key business strategies such as mergers and acquisitions(M&A), affiliations, collaborations, and contracts adopted by the major players are also recognized and analyzed in the report. For each company, the report recognizes their manufacturing base, competitors, product type, application and specification, pricing, and gross margin.

Key Benefits for Industry Participants & Stakeholders:

• Industry drivers, restraints, and opportunities covered in the study
  • Neutral viewpoint on the market performance
  • Recent industry trends and developments
  • Competitive landscape & approaches of major players
  • Potential & niche segments and regions exhibiting promising growth covered
  • Historical, current, and projected market size, in terms of value
  • Detailed analysis of the Ankylosing Spondylitis Market

Contact Us:

Company: Absolute Markets Insights

Email Id: sales@absolutemarketsinsights.com

Phone: IN +917400242424, US +1-510-420-1213

Contact Name: Shreyas Tanna

Website: www.absolutemarketsinsights.com/